Recombinant Human DSPG3 Protein, CF

Catalog #: 3110-DS Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
3110-DS-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human DSPG3 Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

Activity

Measured by the ability of the immobilized protein to enhance the adhesion of Saos‑2 human osteosarcoma cells to human Fibronectin. When 5 x 10⁴ cells/well are added to Human DSPG3 and Recombinant Human Fibronectin (0.5 μg/mL, (Catalog # 4305-FNB) coated plates, the cell adhesion is enhanced in a dose dependent manner. The ED₅₀ for this effect is 0.05-1 μg/mL.
Optimal dilutions should be determined by each laboratory for each application.

Source

Mouse myeloma cell line, NS0-derived human DSPG3 protein
Met1-Val322 with a C-terminal 10-His tag

Accession #

Q99645

N-terminal Sequence
Analysis

Ala20

Predicted Molecular Mass

36 kDa

SDS-PAGE

50-60 kDa, reducing conditions

Product Datasheets

3110-DS

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

3110-DS

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 200 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: DSPG3

Human DSPG3 (dermatan sulfate proteoglycan 3), also called epiphycan (gene name EPYC) or PG-Lb, is a 95-100 kDa class III subfamily member of the SLRP (small leucine-rich proteoglycans) family of molecules (1-4). It is synthesized as a 322 amino acid (aa) precursor that contains a 19 aa signal sequence and a 303 aa mature region. The mature molecule contains three N-terminal O-glycosylation sites (including one found to bind dermatin sulfate) and a glutamic acid-rich motif followed by six leucine-rich repeats (LRR) that contain two potential N-glycosylation sites (2, 3). The LRR are flanked by two intrachain disulfide bonds (5). Class III SLRPs, including DSPG3, Osteoglycin and Opticin, contain 6-7 LRR, while other classes contain 8 ‑ 10 LRR (1, 4). Collagen binding maps to the LRR (1). Mature human DSPG3 shares 84%, 85%, 95% and 96% aa sequence identity with mouse, rat, bovine and canine DSPG3, respectively. DSPG3 is found predominantly in epiphyseal cartilage, although DSPG3 mRNA is also detected in mouse testis and human ligament and placenta (2-4). In mouse, expression begins in mid-gestation as an intermediate marker for chondrogenesis, peaks at birth and declines thereafter (6, 7). Deletion of DSPG3 in mouse results in a mild postnatal phenotype that worsens synergistically when the co‑expressed SLRP biglycan is also deleted (7). The double-mutant phenotype includes premature osteoarthritis, indicating a role for DSPG3, in cooperation with other SLRPs, in stability of the collagen matrix and maintenance of joint integrity (7).

References

Kalamajski, S. and A. Oldberg (2010) Matrix Biol. 29:248.
Kurita, K. et al. (1996) Biochem. J. 318:909.
Deere, M. et al. (1996) Genomics 38:399.
Deere, M. et al. (1999) Genome Res. 9:449.
Swiss-Prot Accession # Q96645 and P70186.
Johnson, J. et al. (1999) Dev. Dyn. 216:499.
Nuka, S. et al. (2010) Osteoarthritis Cartilage 18:88.

Long Name

Dermatan Sulfate Proteoglycan 3

Entrez Gene IDs

1833 (Human); 13516 (Mouse)

Alternate Names

Dermatan sulfate proteoglycan 3dermatan sulphate proteoglycan 3; DSPG3; DSPG3proteoglycan-lb; Epiphycan; EPYC; PGLB; PG-Lb; Proteoglycan-Lb; SLRR3B; SLRR3Bepiphycan proteoglycan; Small chondroitin/dermatan sulfate proteoglycan